Feb 12 - Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.
The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said.
Advair targets certain patients with asthma or chronic obstructive pulmonary disease and brought in revenue of about $4.19 billion in 2017 for the London-listed GSK.
Mylan received approval for the treatment from the U.S. Food and Drug Administration last month.
In the United States, more than 26 million people are known to have asthma, of which about seven million are children.
The FDA has declined to approve several Advair copycats including those from Novartis AG and Hikma Pharmaceuticals.
Mylan's shares gained 1.4 percent at $31.46 in morning trade.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Sriraj Kalluvila)
2月12日-美兰公司周二将其仿制药葛兰素史克（GlaxoSmithKline）公司的哮喘治疗药物 Advair 的定价比品牌药低70%。
该公司表示，这是 Advair 的首个仿制药，三次获得批准，定价在93.71美元至153.14美元之间。
上个月，迈兰（Mylan）获得了美国食品药品监督管理局（Food and Drug Administration）的批准。
FDA 拒绝批准包括诺华公司（ Novartis AG ）和希克玛制药（ Hikma Pharmaceuticals ）在内的几种 Advair 仿制药。
( Aakash Jagadeesh Babu 在 Bengaluru 的报告； Sriraj Kalluvila 的编辑)